A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Recruiting now · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.

Key facts

Study ID
NCT07229729
Run by
Shanghai Hengrui Pharmaceutical Co., Ltd.
People needed
300
Starts
2025-11-24
Expected to finish
2029-10-01
Last updated by the study team
2025-12-01

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.